10 Results for "

losmapimod fshd

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "losmapimod fshd" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-10402
CAS No.: 585543-15-3
Purity:  99.94%
Synonyms: GSK-AHAB; GW856553X; SB856553
Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pKi values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99588
CAS No.: 705287-60-1
Synonyms: MYO-029

Target:  

TGF-β Receptor

Research Areas:  

Metabolic Disease

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153866
CAS No.: 1383376-92-8
Purity:  99.54%
Target:  

Casein Kinase

Research Areas:  

Cancer

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively .
loading...
    loading...
Cat. No.: HY-177971
Braxlosiran is a component of the AOC reagent Delpacibart braxlosiran (HY-177566), consisting of an siRNA targeting DUX4 (double homeobox protein) and SMCC linker (HY-42360). Delpacibart braxlosiran binds to TfR1. Aberrant expression of the DUX4 protein causes changes in gene expression in muscle cells, which are associated with muscle function loss in facioscapulohumeral muscular dystrophy (FSHD) .
loading...
    loading...
Cat. No.: HY-10402R
CAS No.: 585543-15-3
Synonyms: GSK-AHAB (Standard); GW856553X (Standard); SB856553 (Standard)
Losmapimod (GSK-AHAB; GW856553X) (Standard) is the analytical standard of Losmapimod (HY-10402). This product is intended for research and analytical applications. Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pKi values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity .
loading...
    loading...
Cat. No.: HY-153866A
CAS No.: 1383377-49-8
Target:  

Casein Kinase

Research Areas:  

Cancer

CK1-IN-2 (compound Nr.4) hydrochloride is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively .
loading...
    loading...
Cat. No.: HY-171277
CAS No.: 1095706-65-2
Target:  

Casein Kinase p38 MAPK

Research Areas:  

Cancer

Casein kinase 1δ-IN-27 (Compound 8) is the inhibitor for casein kinase 1 that inhibits CK1α, CK1δ, CK1ε, and p38α with IC50s of 22, 16.5, 9.41 and 14.8 nM, respectively. Casein kinase 1δ-IN-27 inhibits the DUX4 expression with an IC50 of 10 nM .
loading...
    loading...
Cat. No.: HY-10402A
CAS No.: 1246654-84-1
Synonyms: GSK-AHAB hydrochloride; GW856553X hydrochloride; SB856553 hydrochloride
Losmapimod (GSK-AHAB; GW856553X) hydrochloride is an orally active p38α/β MAPK inhibitor, with pKi values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod hydrochloride reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod hydrochloride reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod hydrochloride blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod hydrochloride overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod hydrochloride inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity .
loading...
    loading...
Cat. No.: HY-P82826
Synonyms: BAMS; fshd2; Smchd1

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P86880
Synonyms: frg1 antibody; FRG1_HUMAN antibody; FRG1A antibody; FSG1 antibody; fshd region gene 1 protein antibody; Protein FRG1 antibody;

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human

loading...
    loading...